ERK-mediated phosphorylation of TFAM downregulates mitochondrial transcription: implications for Parkinson's disease.

Wang KZ, Zhu J, Dagda RK, Uechi G, Cherra SJ 3rd, Gusdon AM, Balasubramani M, Chu CT.

Mitochondrion. 2014 Jul;17:132-40. doi: 10.1016/j.mito.2014.04.008.

Sensitive measures of executive dysfunction in non-demented Parkinson's disease.

Bott NT, Johnson ET, Schuff N, Galifianakis N, Subas T, Pollock J, Pressman P, Kramer JH, Possin KL.

Parkinsonism Relat Disord. 2014 Dec;20(12):1430-3. doi: 10.1016/j.parkreldis.2014.10.007.

Modeling Lewy pathology propagation in Parkinson's disease.

Luk KC, Lee VM.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S85-7. doi: 10.1016/S1353-8020(13)70022-1. Review.

NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.

El Arfani A, Bentea E, Aourz N, Ampe B, De Deurwaerdère P, Van Eeckhaut A, Massie A, Sarre S, Smolders I, Michotte Y.

Neuropharmacology. 2014 Oct;85:198-205. doi: 10.1016/j.neuropharm.2014.05.024.

A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease.

Dranka BP, Gifford A, McAllister D, Zielonka J, Joseph J, O'Hara CL, Stucky CL, Kanthasamy AG, Kalyanaraman B.

Neurosci Lett. 2014 Nov 7;583:159-64. doi: 10.1016/j.neulet.2014.09.042.

Improving functional disability and cognition in Parkinson disease: randomized controlled trial.

Peña J, Ibarretxe-Bilbao N, García-Gorostiaga I, Gomez-Beldarrain MA, Díez-Cirarda M, Ojeda N.

Neurology. 2014 Dec 2;83(23):2167-74. doi: 10.1212/WNL.0000000000001043.

Mutation in Drosophila methuselah resists paraquat induced Parkinson-like phenotypes.

Shukla AK, Pragya P, Chaouhan HS, Patel DK, Abdin MZ, Kar Chowdhuri D.

Neurobiol Aging. 2014 Oct;35(10):2419.e1-2419.e16. doi: 10.1016/j.neurobiolaging.2014.04.008.

Parkinson's disease and carotid intima-media thickness.

Alexa D, Constantinescu A, Baltag D, Ignat B, Bolbocean O, Popescu CD.

Rev Med Chir Soc Med Nat Iasi. 2014 Jan-Mar;118(1):52-6.

The potential of alternate sources of cells for neural grafting in Parkinson's and Huntington's disease.

Drouin-Ouellet J.

Neurodegener Dis Manag. 2014;4(4):297-307. doi: 10.2217/nmt.14.26. Review.

Specific changes of serum proteins in Parkinson's disease patients.

Lu W, Wan X, Liu B, Rong X, Zhu L, Li P, Li J, Wang L, Cui L, Wang X.

PLoS One. 2014 Apr 25;9(4):e95684. doi: 10.1371/journal.pone.0095684.

The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease.

Spalletta G, Robinson RG, Cravello L, Pontieri FE, Pierantozzi M, Stefani A, Long JD, Caltagirone C, Assogna F.

J Neurol. 2014 Jun;261(6):1126-32. doi: 10.1007/s00415-014-7327-6.

A putative founder effect for Parkinson's disease in South African Afrikaners.

Carr J, van Coller R.

S Afr Med J. 2014 Apr 28;104(6):411-2. doi: 10.7196/samj.8390. No abstract available.

Physical training prevents depressive symptoms and a decrease in brain-derived neurotrophic factor in Parkinson's disease.

Tuon T, Valvassori SS, Dal Pont GC, Paganini CS, Pozzi BG, Luciano TF, Souza PS, Quevedo J, Souza CT, Pinho RA.

Brain Res Bull. 2014 Sep;108:106-12. doi: 10.1016/j.brainresbull.2014.09.006.

Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment.

Christopher L, Marras C, Duff-Canning S, Koshimori Y, Chen R, Boileau I, Segura B, Monchi O, Lang AE, Rusjan P, Houle S, Strafella AP.

Brain. 2014 Feb;137(Pt 2):565-75. doi: 10.1093/brain/awt337.

Redundant dopaminergic activity may enable compensatory axonal sprouting in Parkinson disease.

Arkadir D, Bergman H, Fahn S.

Neurology. 2014 Mar 25;82(12):1093-8. doi: 10.1212/WNL.0000000000000243.